17 studies found for:    Open Studies | spectrum pharmaceuticals
Show Display Options
Rank Status Study
1 Recruiting A Phase 3 Study to Evaluate Marqibo® in the Treatment of Subjects ≥ 60 Years Old With Newly Diagnosed ALL
Condition: Acute Lymphoblastic Leukemia (ALL)
Interventions: Drug: Vincristine Sulfate Liposomes Injection (VSLI);   Drug: Vincristine Sulfate Injection (VSI)
2 Not yet recruiting Phase 2, Single Arm, Open Label Study of Folotyn in Combination With Oral Leucovorin to Prevent or Reduce Mucositis in Patients With PTCL
Conditions: Relapsed Peripheral T-Cell Lymphoma;   Refractory Peripheral T-Cell Lymphoma
Interventions: Drug: Folotyn and Leucovorin;   Drug: Folic Acid;   Drug: Vitamin B12
3 Recruiting Phase 2 Study of HM10460A or Pegfilgrastim Use for the Management of Neutropenia in Breast Cancer Patients
Condition: Neutropenia
Interventions: Drug: HM10460A (45 μg/kg);   Drug: HM10460A (135 μg/kg);   Drug: HM10460A (270 μg/kg);   Drug: Pegfilgrastim 6mg
4 Recruiting Study of Pralatrexate Versus Observation Following CHOP-based Chemotherapy in Previously Undiagnosed Peripheral T-cell Lymphoma Patients
Condition: Peripheral T-cell Lymphoma
Intervention: Drug: Pralatrexate Injection
5 Recruiting Study of Zevalin Versus Observation in Patients at Least 60 Yrs Old With Newly Diagnosed Diffuse Large B-cell Lymphoma in PET-negative Complete Remission After R-CHOP or R-CHOP-like Therapy
Conditions: Diffuse Large B-cell Lymphoma;   Follicle Center Lymphoma
Intervention: Drug: Zevalin (ibritumomab tiuxetan)
6 Recruiting Phase II Study of SPI-1620 in Combination With Docetaxel as a Second-Line to Treat Biliary Cancer
Condition: Biliary Cancer
Intervention: Drug: SPI-1620 & Docetaxel
7 Recruiting Phase 1 Dose Finding Study of Belinostat for Treatment of Patients With Peripheral T-cell Lymphoma (PTCL)
Condition: Peripheral T-cell Lymphoma
Interventions: Drug: Belinostat;   Drug: CHOP
8 Recruiting Zevalin-Containing Nonmyeloablative Conditioning for Stem Cell Transplantation (SCT)
Conditions: Leukemia;   Lymphoma
Interventions: Drug: Rituximab;   Drug: 111In Ibritumomab;   Procedure: Planar Scintigraphy Imaging;   Drug: 90Y IbritumomabTiuxetan;   Drug: Fludarabine;   Drug: Bendamustine;   Drug: Thymoglobulin;   Drug: Tacrolimus;   Drug: Methotrexate;   Drug: Mycophenolate;   Drug: G-CSF;   Procedure: Stem Cell Transplantation
9 Recruiting Evaluation of Lucanthone to Whole Brain Radiation Therapy in Patients With Brain Metastases From Non-Small Cell Lung Cancer
Conditions: Brain Metastases;   Non-small Cell Lung Cancer
Intervention: Drug: Lucanthone
10 Recruiting Bendamustine and Rituximab Followed by 90-yttrium (Y) Ibritumomab Tiuxetan for Untreated Follicular Lymphoma
Condition: Lymphoma, Follicular
Interventions: Drug: Bendamustine;   Drug: Rituximab;   Radiation: Y-90 ibritumomab
11 Recruiting Zevalin Before Stem Cell Transplant in Treating Patients With Non-Hodgkin Lymphoma
Conditions: Refractory Non Hodgkin Lymphoma;   Relapsed Non Hodgkin Lymphoma
Interventions: Biological: rituximab;   Biological: ibritumomab tiuxetan;   Biological: anti-thymocyte globulin;   Radiation: total nodal irradiation;   Procedure: peripheral blood stem cell transplantation;   Procedure: allogeneic hematopoietic stem cell transplantation;   Drug: cyclosporine;   Drug: mycophenolate mofetil;   Other: laboratory biomarker analysis
12 Recruiting Zevalin and Velcade in Relapsed/Refractory Mantle Cell Lymphoma
Condition: Mantle-Cell Lymphoma
Intervention: Drug: Rituximab, Bortezomib,Y90 ibritumomab tiuxetan
13 Recruiting Hyper-CVAD With Liposomal Vincristine in Acute Lymphoblastic Leukemia
Condition: Leukemia
Interventions: Drug: Rituximab;   Drug: Imatinib;   Drug: Cyclophosphamide;   Drug: Doxorubicin;   Drug: Mesna;   Drug: VSLI;   Drug: Solu-Medrol;   Drug: Methotrexate;   Drug: Ara-C;   Drug: G-CSF;   Drug: Pegfilgrastim;   Drug: Dexamethasone
14 Recruiting Post-Transplant Bortezomib and High Dose Cyclophosphamide as Graft-Versus-Host Disease (GVHD) Prophylaxis
Condition: Hematological Malignancy
Interventions: Drug: Cohort 1-Bortezomib (Velcade ®);   Drug: Cohort 2-Bortezomib (Velcade ®);   Drug: Cohort 3-Bortezomib (Velcade ®)
15 Recruiting Preventative Trial of DFMO in Patients With High Risk Neuroblastoma in Remission
Condition: Neuroblastoma in Remission
Intervention: Drug: DFMO
16 Recruiting Behavioral Treatment of Adolescent Substance Use
Condition: Substance Use Disorders
Interventions: Behavioral: Behavior Therapy;   Behavioral: Working Memory Training
17 Recruiting Pheno- & Genotyping POF (WHO III)
Conditions: Premature Ovarian Failure (POF);   Incipient Ovarian Failure;   Poor Response After Ovarian Hyperstimulation;   Early Menopause;   Hypergonadotropic Amenorrhea
Intervention:

Indicates status has not been verified in more than two years